XML 19 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]    
Molecular diagnostic testing $ 165.1 $ 171.9
Pharmaceutical and clinical services 12.4 11.6
Total revenue 177.5 183.5
Costs and expenses:    
Cost of molecular diagnostic testing 34.3 30.9
Cost of pharmaceutical and clinical services 5.7 5.6
Research and development expense 19.4 17.2
Selling, general, and administrative expense 111.9 86.5
Total costs and expenses 171.3 140.2
Operating income 6.2 43.3
Other income (expense):    
Interest income 0.3 0.1
Other (2.5) 0.1
Total other income (expense): (2.2) 0.2
Income before income tax 4.0 43.5
Income tax provision 5.2 13.2
Net income (loss) (1.2) 30.3
Net income (loss) attributable to non-controlling interest 0.0 0.0
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (1.2) $ 30.3
Earnings (loss) per share:    
Basic $ (0.02) $ 0.44
Diluted $ (0.02) $ 0.42
Weighted average shares outstanding:    
Basic 68.8 68.7
Diluted 68.8 72.1